XML 46 R36.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Interest in joint venture (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Interests In Other Entities [Abstract] |
Schedule of movement in interest in joint venture | The table below provides a rollforward of the Company’s interest in Overland ADCT BioPharma as of September 30, 2022 and 2021, respectively.
(in KUSD) |  |
Interest in joint venture |  |
January 1, 2022 |  | 41,236 |
Share of results in joint venture |  | (6,549) |
September 30, 2022 |  | 34,687 |
January 1, 2021 |  | 47,908 |
Share of results in joint venture |  | (3,906) |
September 30, 2021 |  | 44,002 |
Summary of financial information in join venture | The tables below provide summarized financial information for Overland ADCT BioPharma that is material to the Company. The following information reflects the amounts presented in the financial statements of Overland ADCT BioPharma and not the Company’s share of those amounts.
(in KUSD) |  | As of |  |  |  |
Summarized Balance Sheet |  | September 30, 2022 |  | December 31, 2021 |  |  |  |
Cash and cash equivalents |  | 24,445 |  |  | 39,318 |  |  |  |  |
Prepaid and other current assets |  | 516 |  |  | 15 |  |  |  |  |
Intangible assets |  | 48,040 |  |  | 48,040 |  |  |  |  |
Total liabilities |  | 3,711 |  |  | 2,828 |  |  |  |  |
Net assets |  | 69,290 |  |  | 84,545 |  |  |  |  |
Summarized Statement of Comprehensive Loss |  | Three months ended September 30, |  | Nine months ended September 30,
|  | 2022 |  | 2021 |  | 2022 |  | 2021
Operating expenses |  | 4,950 |  |  | 4,465 |  |  | 14,317 |  |  | 8,120 |
Net loss |  | 4,346 |  |  | 4,511 |  |  | 13,009 |  |  | 7,972 |

X
- Definition Interests In Other Entities [Abstract] + References No definition available. + Details
Name: | adc_InterestsInOtherEntitiesAbstract
Namespace Prefix: | adc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of interests in joint arrangements. A joint arrangement is an arrangement of which two or more parties have joint control. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2022-03-24 -Paragraph 2 -Subparagraph b -Clause ii -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_2_b_ii&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the reconciliation of the summarised financial information of a joint venture accounted for using the equity method to the carrying amount of the reporting entity's interest in the joint venture. [Refer: Carrying amount [member]; Joint ventures [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2022-03-24 -Paragraph B14 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B14_b&doctype=Appendix&subtype=B -URIDate 2022-03-24 + Details
Name: | ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration